The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of
schizophrenia. Both were initially based on indirect evidence from pharmacological studies …

Ketamine was introduced into clinical practice in the 1960s and continues to be both
clinically useful and scientifically fascinating. With considerably diverse molecular targets …

Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

Aims Ketamine remains an important medicine in both specialist anaesthesia and aspects of
pain management. At the same time, its use as a recreational drug has spread in many parts …

The N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis has been proposed to
help understand the etiology and pathophysiology of schizophrenia. This hypothesis was …

Placing a patient in a state of general anesthesia is crucial for safely and humanely
performing most surgical and many nonsurgical procedures. How anesthetic drugs create …

Background: At least 10-20% of the patients suffering from depression meet criteria for
treatment-resistant depression (TRD). In the last decades, an important role of glutamate in …

Ketamine was discovered in the 1960s and released for public use in 1970. Originally
developed as a safer alternative to phencyclidine, ketamine is primarily used in clinical …

Objective: Ketamine has demonstrated rapid antidepressant effects in patients with
treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this …

Rationale Although there is considerable interest in how either executive function (EF) or
impulsivity relate to addiction, there is little apparent overlap between these research areas …